胰高血糖素样肽1受体激动剂在药物成瘾中的作用研究进展

Research advance in roles of glucagon-like peptide-1 receptor agonists in drug addiction

药物成瘾是全球性的重大医学生物学和社会问题,目前临床上尚缺乏理想的治疗药物。胰高血糖素样肽1(GLP-1)作为一种关键的肠脑肽,其受体激动剂目前已被批准用于治疗2型糖尿病和肥胖症。近年来,GLP-1受体(GLP-1R)激动剂在对抗药物成瘾中的作用受到越来越多的关注。本文将在概述GLP-1系统及GLP-1R激动剂的基础上,以成瘾性精神活性物质(包括酒精、烟草、可卡因、阿片类和苯丙胺类)为主线,从非临床和临床2个水平对GLP-1R激动剂在药物成瘾中的作用进行综述,同时展望其未来发展方向,以期为药物成瘾机制的阐明和治疗药物的研发提供新的线索。

Drug addiction is a major medical and social issue globally,but there is still a lack of ideal clinical treatments.Glucagon-like peptide-1(GLP-1),a key gut-brain peptide,and its receptor agonists have been approved for the treatment of type 2 diabetes and obesity.In recent years,the role of GLP-1 receptor agonists in combating drug addiction has received increasing attention.Based on an overview of the GLP-1 system and its receptor agonist,this article reviews the role of GLP-1 receptor agonists in drug addiction at both the nonclinical and clinical levels by focusing on addictive psychoactive substances(including alcohol,tobacco,cocaine,opioids,and amphetamines).Future developments are also predicted to provide new clues to the mechanism of drug addiction and development of therapeutic drugs.